ATAI Life Sciences Embraces Bitcoin Treasury Strategy to Hedge Against Inflation

ATAI Life Sciences, a Germany-based biopharmaceutical company, has announced that it will allocate a portion of its treasury assets to bitcoin in an effort to preserve and optimize its capital amid inflation and market volatility. The company plans to invest an initial $5 million in bitcoin while maintaining sufficient liquidity for operational expenses until 2027. This move, inspired by the popular bitcoin treasury strategy advocated by Michael Saylor, reflects a growing trend among corporations seeking to secure their balance sheets with cryptocurrency. Following the announcement, ATAI experienced a brief surge in its value before a decline of 2.8% was recorded, suggesting mixed short-term reactions from the market. Meanwhile, bitcoin's price temporarily surpassed $87,000 before settling around $83,900, indicating modest volatility as it adjusts in response to the news.